Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2024 Feb 22;14:1383375. doi: 10.3389/fonc.2024.1383375

Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

Frontiers Editorial Office*
PMCID: PMC10918435  PMID: 38454926

The journal retracts the 2023 article cited above.

Following publication, the publisher identified concerns regarding the scope and peer review of this article. A subsequent investigation, which was conducted in accordance with Frontiers’ policies, found indicators of third-party involvement and inadequate peer review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the article is retracted.

The authors have not responded to this retraction.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES